Spending on Dual Over-the-Counter and Prescription Drugs in the Medicare Part D Program

JAMA. 2024 Jan 2;331(1):72-75. doi: 10.1001/jama.2023.23126.

Authors

Mariana P Socal¹, Yuchen Wang¹, Elizabeth Plummer², Gerard F Anderson¹, Ge Bai³

Affiliations

¹ Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.
² Neeley School of Business, Texas Christian University, Fort Worth.
³ Johns Hopkins Carey Business School, Washington, DC.

PMID: 38095888
PMCID: PMC10722384 (available on 2024-06-14)
DOI: 10.1001/jama.2023.23126

No abstract available

Plain language summary

This study compares Medicare and patient spending for dual over-the-counter and prescription drugs with their over-the-counter cash prices.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Aged
Drug Costs
Health Expenditures
Humans
Medicare Part D* / economics
Nonprescription Drugs* / economics
Prescription Drugs* / economics
Prescriptions / economics
United States

Substances

Prescription Drugs
Nonprescription Drugs